Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd has announced the esteemed Professor Daniel Von Hoff as an addition to their Clinical Advisory Board, bringing his expertise in clinical development to the company’s reformulated drug, RC220 bisantrene. Professor Von Hoff is recognized for his extensive work in translational medicine and has a rich history with bisantrene, including its initial clinical studies. His involvement is expected to significantly advance Race’s clinical and commercial strategies for RC220 bisantrene, aimed at improving cancer care with less cardiotoxicity.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
